Replies to post #110018 on Biotech Values

[10nisman]

Peter’s estimate is off by about a factor of 2. Teva’s annualized net profit is about $4.2B, which means that Teva’s potential after-tax profit from generic Lovenox in the US would at most boost Teva’s EPS by a single-digit %.

I just finished writing a long winded response saying virtual the same thing. So, I'll save everyone my write-up and just say I completely agree with Dew (as I have at most a 7% boost to EPS).

10nis

[biomaven0]

Peter’s estimate is off by roughly 2x.

Yes - it was a quickie back-of-envelope calculation that was indeed off. More like $150m/yr in profits to Teva for a long time to come, which is still not peanuts.

Peter